The medical landscape is undergoing a seismic shift with the rise of GLP-1 (glucagon-like peptide-1) diabetes and weight-loss treatments. Novo Nordisk’s Ozempic and Wegovy, along with Eli Lilly’s Mounjaro, have been at the forefront of this revolution. These treatments, originally developed for managing type-2 diabetes, have shown remarkable efficacy in…
